Business
Patient Stratification Biomarkers for Liver Cancer
Patient Stratification Biomarkers for Liver Cancer.
About this update from Proteome Sciences Plc
[{"type":"text","content":"\n \nRNS Number : 4004T Proteome Sciences PLC 20 November 2013 \n \n\n \n \n \nProteome Sciences plc\n(\"Proteome Sciences\" or the \"Company\")\nNovel Patient Stratification Biomarkers for Liver Cancer\n20th November, 2013. Proteome Sciences is pleased to announce the discovery and validation of novel protein biomarkers for patient stratification in liver cancer using proprietary proteomics workflows. Details are published today in the journal EuPA Open Proteomics: \"Protein expression profiles of chemo-resistant mixed phenotype liver tumors using laser microdissection and LC-MS/MS proteomics\"\n(http://www.sciencedirect.com/science/article/pii/S221296851300007X).\n \nThe study was performed in partnership with Professor Nigel Heaton and his team at Kings College Hospital NHS Foundation Trust and used PS Biomarker Services™ leading edge proteomic workflows. \nEffective treatment of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) remains one of the toughest challenges for doctors, with a five year survival rate of only 13%, barely improved since the 1970's. Prior to the discovery of these biomarkers, definition of the sub-types of liver cancer which require different treatment options, has been extremely difficult.\nAfter completing the analysis of 2,864 proteins, a panel of differentially expressed biomarkers was identified and patents were filed prior to publication to cover these novel stratification markers. \nCommenting on the EuPA publication Professor Nigel Heaton, Director of the King's Liver Transplant Centre said:-\n \"The biomarkers published in EuPA Open Proteomics represent a major step towards improving the outcomes in the treatment of liver cancer. We have been waiting for over 30 years for better treatment options in liver cancer and a large part of the challenge has been the lack of effective biomarkers to differentiate hepatocellular carcinoma and cholangiocarcinoma. Proteome Sciences' proprietary workflows for FFPE tissue for the first time provided a highly effective way of identifying biomarkers for liver cancer and we need to accelerate further validation before moving to widespread clinical adoption.\" \nDr. Ian Pike, Chief Operating Officer of Proteome Sciences added:-\n\"Stratified medicine is a key component of the global response to major ...